ArticleFrontiers in cardiovascular medicine2026
Effects of the active parts of Yangxin Tongmai Formula on myocardial injury and spatial metabolic remodeling in rats with myocardial ischemia-reperfusion injury.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the protective effects of the active parts of Yangxin Tongmai Formula (apr-YTF) against myocardial ischemia-reperfusion injury (MIRI) in rats from the perspective of spatial metabolic remodeling. Methods: A rat model of MIRI with blood stasis syndrome was established. Rats were randomized into Control, Model, Vehicle, and apr-YTF groups. apr-YTF was administered by gavage for 14 days. Cardiac function and myocardial injury were assessed by echocardiography, serum myocardial enzyme assays, triphenyltetrazolium chloride (TTC) staining, and hematoxylin and eosin (HE) staining. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was used to analyze the spatial distribution patterns and metabolic profiles of differential metabolites in myocardial tissue. Results: apr-YTF significantly improved left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS), reduced serum creatine kinase (CK), creatine kinase-MB isoenzyme (CK-MB), lactate dehydrogenase (LDH), and lactate dehydrogenase 1 (LDH1) levels, decreased infarct size, and alleviated myocardial fibrosis and inflammatory infiltration. MALDI-MSI identified 1,282 metabolites, including 702 MIRI model-associated differential metabolic features, mainly including amino acids, nucleotides, and glycerophospholipids. The MIRI group exhibited extensive metabolic remodeling involving lipid, amino acid, nucleotide metabolism, and cofactor biosynthesis pathways. After apr-YTF intervention, 17 reversed differential metabolic features showed recovery trends. Conclusion: The active parts of Yangxin Tongmai Formula ameliorated myocardial injury and were associated with partial correction of spatial metabolic remodeling in rats with MIRI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.